Pivotal results of SELECT-MDS-1 phase 3 study of tamibarotene with azacitidine in newly diagnosed higher-risk MDS.

DeZern AE, Thepot S, de Botton S, Patriarca A, Deeren D, Torregrossa-Diaz JM, Marconi G, Bernal T, Bergua Burgues J, Xicoy B, Jonášová A, Zeidan AM, Dimicoli-Salazar S, Simand C, Valcarcel D, Diez Campelo M, Chai-Ho W, Saini L, Garnier A, Geissler K, Ofran Y, Nagy Z, Krishnamurthy P, Lübbert M, Basak G, Carraway HE, Sallman DA, Borate U, Santini V, Campbell V, Fenaux P, Braun T, Lanza F, Zaucha JM, Roth DA, Paul S, Roy P, Kelly MJ, Volkert A, Chisholm J, Malak TA, Klimek VM, Cluzeau T

Open source

DOI
10.1182/bloodadvances.2025016229
Published
2025 Aug 26
Container
Blood advances
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1182/bloodadvances.2025016229,
  title = {Pivotal results of SELECT-MDS-1 phase 3 study of tamibarotene with azacitidine in newly diagnosed higher-risk MDS.},
  author = {DeZern AE and Thepot S and de Botton S and Patriarca A and Deeren D and Torregrossa-Diaz JM and Marconi G and Bernal T and Bergua Burgues J and Xicoy B and Jonášová A and Zeidan AM and Dimicoli-Salazar S and Simand C and Valcarcel D and Diez Campelo M and Chai-Ho W and Saini L and Garnier A and Geissler K and Ofran Y and Nagy Z and Krishnamurthy P and Lübbert M and Basak G and Carraway HE and Sallman DA and Borate U and Santini V and Campbell V and Fenaux P and Braun T and Lanza F and Zaucha JM and Roth DA and Paul S and Roy P and Kelly MJ and Volkert A and Chisholm J and Malak TA and Klimek VM and Cluzeau T},
  year = {2025},
  journal = {Blood advances},
  doi = {10.1182/bloodadvances.2025016229},
  url = {https://doi.org/10.1182/bloodadvances.2025016229}
}

RIS

TY  - JOUR
TI  - Pivotal results of SELECT-MDS-1 phase 3 study of tamibarotene with azacitidine in newly diagnosed higher-risk MDS.
AU  - DeZern AE
AU  - Thepot S
AU  - de Botton S
AU  - Patriarca A
AU  - Deeren D
AU  - Torregrossa-Diaz JM
AU  - Marconi G
AU  - Bernal T
AU  - Bergua Burgues J
AU  - Xicoy B
AU  - Jonášová A
AU  - Zeidan AM
AU  - Dimicoli-Salazar S
AU  - Simand C
AU  - Valcarcel D
AU  - Diez Campelo M
AU  - Chai-Ho W
AU  - Saini L
AU  - Garnier A
AU  - Geissler K
AU  - Ofran Y
AU  - Nagy Z
AU  - Krishnamurthy P
AU  - Lübbert M
AU  - Basak G
AU  - Carraway HE
AU  - Sallman DA
AU  - Borate U
AU  - Santini V
AU  - Campbell V
AU  - Fenaux P
AU  - Braun T
AU  - Lanza F
AU  - Zaucha JM
AU  - Roth DA
AU  - Paul S
AU  - Roy P
AU  - Kelly MJ
AU  - Volkert A
AU  - Chisholm J
AU  - Malak TA
AU  - Klimek VM
AU  - Cluzeau T
PY  - 2025
JO  - Blood advances
DO  - 10.1182/bloodadvances.2025016229
UR  - https://doi.org/10.1182/bloodadvances.2025016229
ER  -

APA

AE, D., S, T., S, D. B., A, P., D, D., JM, T., G, M., T, B., J, B. B., B, X., A, J., AM, Z., S, D., C, S., D, V., M, D. C., W, C., L, S., A, G., K, G., Y, O., Z, N., P, K., M, L., G, B., HE, C., DA, S., U, B., V, S., V, C., P, F., T, B., F, L., JM, Z., DA, R., S, P., P, R., MJ, K., A, V., J, C., TA, M., VM, K., & T, C. (2025). Pivotal results of SELECT-MDS-1 phase 3 study of tamibarotene with azacitidine in newly diagnosed higher-risk MDS.. Blood advances. https://doi.org/10.1182/bloodadvances.2025016229

Source records